Cargando…

The risk of angiosarcoma following primary breast cancer

Lymphangiosarcoma of the upper extremity is a rare and aggressive tumour reported to occur following post-mastectomy lymphoedema (Stewart–Treves syndrome). Haemangiosarcoma, a related rare tumour, has occasionally been reported to occur in the breast following irradiation. We conducted a case-contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Cozen, W, Bernstein, L, Wang, F, Press, M F, Mack, T M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362921/
https://www.ncbi.nlm.nih.gov/pubmed/10507781
http://dx.doi.org/10.1038/sj.bjc.6690726
_version_ 1782153574520717312
author Cozen, W
Bernstein, L
Wang, F
Press, M F
Mack, T M
author_facet Cozen, W
Bernstein, L
Wang, F
Press, M F
Mack, T M
author_sort Cozen, W
collection PubMed
description Lymphangiosarcoma of the upper extremity is a rare and aggressive tumour reported to occur following post-mastectomy lymphoedema (Stewart–Treves syndrome). Haemangiosarcoma, a related rare tumour, has occasionally been reported to occur in the breast following irradiation. We conducted a case-control study using the University of Southern California-Cancer Surveillance Program, the population-based cancer registry for Los Angeles County, to evaluate the relationship between invasive female breast cancer and subsequent upper extremity or chest lymphangiosarcoma and haemangiosarcoma together referred to as angiosarcoma. Cases were females diagnosed between 1972 and 1995 with angiosarcoma of the upper extremity (n = 20) or chest (n = 48) who were 25 years of age or older and residing in Los Angeles County when diagnosed. Other sarcomas at the same anatomic sites were also studied. Controls were females diagnosed with cancers other than sarcoma during the same time period (n = 266 444). Cases and controls were then compared with respect to history of a prior invasive epithelial breast cancer. A history of breast cancer increased the risk of upper extremity angiosarcoma by more than 59-fold (odds ratio [OR] = 59.3, 95% confidence interval [95% CI] = 21.9–152.8). A strong increase in risk after breast cancer was also observed for angiosarcoma of the chest and breast (OR = 11.6, 95% CI = 4.3–26.1) and for other sarcomas of the chest and breast (OR = 3.3, 95% CI = 1.1–1.7). © 1999 Cancer Research Campaign
format Text
id pubmed-2362921
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23629212009-09-10 The risk of angiosarcoma following primary breast cancer Cozen, W Bernstein, L Wang, F Press, M F Mack, T M Br J Cancer Regular Article Lymphangiosarcoma of the upper extremity is a rare and aggressive tumour reported to occur following post-mastectomy lymphoedema (Stewart–Treves syndrome). Haemangiosarcoma, a related rare tumour, has occasionally been reported to occur in the breast following irradiation. We conducted a case-control study using the University of Southern California-Cancer Surveillance Program, the population-based cancer registry for Los Angeles County, to evaluate the relationship between invasive female breast cancer and subsequent upper extremity or chest lymphangiosarcoma and haemangiosarcoma together referred to as angiosarcoma. Cases were females diagnosed between 1972 and 1995 with angiosarcoma of the upper extremity (n = 20) or chest (n = 48) who were 25 years of age or older and residing in Los Angeles County when diagnosed. Other sarcomas at the same anatomic sites were also studied. Controls were females diagnosed with cancers other than sarcoma during the same time period (n = 266 444). Cases and controls were then compared with respect to history of a prior invasive epithelial breast cancer. A history of breast cancer increased the risk of upper extremity angiosarcoma by more than 59-fold (odds ratio [OR] = 59.3, 95% confidence interval [95% CI] = 21.9–152.8). A strong increase in risk after breast cancer was also observed for angiosarcoma of the chest and breast (OR = 11.6, 95% CI = 4.3–26.1) and for other sarcomas of the chest and breast (OR = 3.3, 95% CI = 1.1–1.7). © 1999 Cancer Research Campaign Nature Publishing Group 1999-10 /pmc/articles/PMC2362921/ /pubmed/10507781 http://dx.doi.org/10.1038/sj.bjc.6690726 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Cozen, W
Bernstein, L
Wang, F
Press, M F
Mack, T M
The risk of angiosarcoma following primary breast cancer
title The risk of angiosarcoma following primary breast cancer
title_full The risk of angiosarcoma following primary breast cancer
title_fullStr The risk of angiosarcoma following primary breast cancer
title_full_unstemmed The risk of angiosarcoma following primary breast cancer
title_short The risk of angiosarcoma following primary breast cancer
title_sort risk of angiosarcoma following primary breast cancer
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362921/
https://www.ncbi.nlm.nih.gov/pubmed/10507781
http://dx.doi.org/10.1038/sj.bjc.6690726
work_keys_str_mv AT cozenw theriskofangiosarcomafollowingprimarybreastcancer
AT bernsteinl theriskofangiosarcomafollowingprimarybreastcancer
AT wangf theriskofangiosarcomafollowingprimarybreastcancer
AT pressmf theriskofangiosarcomafollowingprimarybreastcancer
AT macktm theriskofangiosarcomafollowingprimarybreastcancer
AT cozenw riskofangiosarcomafollowingprimarybreastcancer
AT bernsteinl riskofangiosarcomafollowingprimarybreastcancer
AT wangf riskofangiosarcomafollowingprimarybreastcancer
AT pressmf riskofangiosarcomafollowingprimarybreastcancer
AT macktm riskofangiosarcomafollowingprimarybreastcancer